Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir
 (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian
 participants with compensated cirrhosis with or without human immunodeficiency virus (HIV)
 co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN)
 (alpha, beta or pegylated interferon [pegIFN]) with or without ribavirin (RBV) OR sofosbuvir
 with RBV with or without IFN.
Inclusion Criteria:

 -  Must be of Asian descent.

 -  Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 1, 2, 3,
 4, 5 or 6 infection.

 -  Positive anti-HCV antibody (Ab) and HCV ribonucleic acid (RNA) greater than or equal
 to 1000 IU/ mL at Screening Visit.

 -  Chronic HCV infection defined as one of the following:

 -  Positive for anti-HCV Ab or HCV RNA at least 6 months before Screening; or

 -  A liver biopsy consistent with chronic HCV infection;

 -  HCV treatment-naïve to any approved or investigational HCV treatment or
 treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon
 [pegIFN] with or without ribavirin (RBV) OR sofosbuvir with RBV with or without IFN.
 Previous treatment must have been completed >= 8 weeks prior to screening.

 -  Compensated cirrhosis defined as Child-Pugh score of ≤ 6 at Screening and no current
 or past clinical evidence of Child-Pugh B or C Classification or clinical history of
 liver decompensation including ascites noted on physical exam, bleeding varices, use
 of diuretics for ascites, or hepatic encephalopathy.

 -  Absence of hepatocellular carcinoma (HCC)

 Participants enrolled with human immunodeficiency virus (HIV)-1 and HCV co-infection must
 also meet the following criteria:

 -  Positive test result for human immunodeficiency virus antibody (HIV Ab) at Screening.

 -  Naïve to treatment with any antiretroviral therapy (ART) with a cluster of
 differentiation (CD)4+ count greater than or equal to 500 cells/mm³ (or CD4+ % >=
 29%), or

 -  On a stable, qualifying HIV-1 ART regimen with CD4+ count >= 200 cells/mm³ (or CD4+ %
 >= 14%) at Screening; and plasma HIV-1 RNA below lower limit of quantification (LLOQ)
 by an approved plasma HIV-1 RNA quantitative assay at Screening and at least once
 during the 12 months prior to Screening.

 Exclusion Criteria:

 -  Positive test result for hepatitis B surface antigen (HbsAg) or positive test result
 for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) if HBsAg is negative.

 -  Any cause of liver disease other than chronic HCV-infection.

 -  HCV genotype performed during screening indicating co-infection with more than one HCV
 genotype

 -  Clinically significant abnormalities, other than HCV infection or HCV/HIV co-infection

 -  Chronic human immunodeficiency virus, type 2 (HIV-2) infection

 Additional Exclusion Criteria for participants with HCV/HIV Co-Infection:

 -  For participants on stable ART, taking anti-retroviral agent(s) other than those
 permitted

 -  Treatment for an acquired immunodeficiency syndrome (AIDS)-associated opportunistic
 infection within 12 months of Screening or prophylaxis for an AIDS-associated
 opportunistic infection within 6 months of screening

 -  Diagnosis of any clinical AIDS-defining event within 12 months prior to Screening.